Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2455-2463

  Toriumi, Fumiki ^a   Kubota, Tetsuro ^a   Saikawa, Yoshiro ^a   Yoshida, Masashi ^a   Otani, Yoshihide ^a   Watanabe, Masahiko ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Chemosensitivity; Dihydropyrimidine dehydrogenase; Gastric cancer; Tandem repeat; Thymidylate synthetase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORIMETRY; DISSOCIATION; DNA SEQUENCE; DRUG TARGETING; FEMALE; GENE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INFORMED CONSENT; MALE; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STOMACH CARCINOMA; TANDEM REPEAT; TS GENE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; COLORIMETRY; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OXONIC ACID; PROMOTER REGIONS (GENETICS); PYRIDINES; RNA, MESSENGER; STOMACH NEOPLASMS; TEGAFUR; TETRAZOLIUM SALTS; THIAZOLES; THYMIDYLATE SYNTHASE;

EID: 4444290662     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kubota T: Is gastric cancer declining? Jpn Med Assoc J 46: 246-250, 2003.
2. Macdonald JS and Gohmann JJ: Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 15 (Suppl. 4): 42-49, 1988.
3. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
4. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
5. Langenbach RJ, Danenberg P and Heidelberger C: Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48:1565-1571, 1972.
6. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S and Pinedo HM: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12: 2035-2042, 1994.
7. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
8. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
9. Leichman CG, Lenz HJ, Leichman L, Danenberg KD, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
10. Peters GJ, Laurensse E, Leyva A, Lankelma J and Pinedo HM: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5- fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46: 20-28, 1986.
11. Aschele C, Sobrero A, Faderan MA and Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedule. Cancer Res 52: 1855-1864, 1992.
12. Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O and Sento T: Human thymidylate synthase gene: Isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. J Biochem 106: 575-583, 1989.
13. Horie N, Aiba H, Oguro K, Hojo H and Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene. Cell Struct Funct 20: 191-197, 1995.
14. Kawakami K and Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63(18): 6004-6007, 2003.
15. Kawakami K, Ishida Y, Danenberg KD, Omura K, Watanabe G and Danenberg PV: Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn J Cancer Res 93(11): 1221-1229, 2002.
16. Marsh S and McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1(3): 175-178, 2001.
17. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointesitinal cancers. Anticancer Res 19: 3249-3252, 1999.
18. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63, 1983.
19. Fujita K, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, Kumai K and Kitajima M: Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer. Anticancer Res 18: 1973-1978, 1998.
20. Abe S, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, Kumai K and Kitajima M: Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res 19: 4581-4586, 1999.
21. Kubota T, Egawa T, Otani Y, Furukawa T, Saikawa Y, Yoshida M, Watanabe M and Kitajima M: Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination. Anticancer Res 23: 583-588, 2003.
22. Kabeshima Y, Kubota T, Watanabe M, Hasegawa H, Yamauchi T, Yorozuya K, Furukawa T, Otani Y and Kitajima M: Clinical usefulness of chemosensitivity testing in evaluating the optimal adjuvant chemotherapy for advanced colorectal cancer. Anticancer Res 22: 3033-8, 2002.
23. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition - Gastric Cancer 1: 10-24, 1998.
24. Iacopetta B, Grieu F, Joseph D and Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85(6): 827-830, 2001.
25. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S and Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19(6): 1779-1786, 2001.
26. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: Possible predictor for sensitivity to 5-fluorouracil. Japanese J Cancer Res 91: 105-112, 2000.
27. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H and Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5: 883-889, 1999.
28. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: A study of 88 surgical specimens. Cancer Sci 94 (7): 633-638, 2003.
29. Kobayashi N, Kubota T, Watanabe M, Otani Y, Teramoto T and Kitajima M: Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively. J Infect Chemother 5: 144-148, 1999.
30. Inada T, Ogata Y, Kubota T, Tomikawa M, Yamamoto S, Andoh J, Ozawa I, Hishinuma S, Shimizu H and Kotake K: 5-Fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer. Anticancer Res 20: 2557-2462, 2000.
31. Suganuma K, Kubota T, Saikawa Y, Abe S, Otani Y, Furukawa T, Kumai K, Hasegawa H, Watanabe M, Kitajima M, Nakayama H and Okabe H: Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 94(4): 355-359, 2003.
32. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 19: 5635-5640, 1999.
33. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano GA: Role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522, 1994.
34. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
35. Jiang W, Lu Z, He Y and Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3: 395-399, 1997.
36. Takechi T, Uchida J, Fujioka A and Fukushima M: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11: 1041-1044, 1997.